Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY:RMD)

249.54 -3.81 (-1.50%)
Streaming Delayed Price Updated: 9:55 AM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Microsoft To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
What 6 Analyst Ratings Have To Say About ResMed
Via Benzinga
Looking Into ResMed's Recent Short Interest
Via Benzinga
Stock Market News From Amazon, Nike, McCormick, and More
We also talk with author Nicola Twilley about her new book, "Frostbite: How Refrigeration Changed Our Food, Our Planet, and Ourselves." 
Via The Motley Fool
Falling Knives: 3 Stocks Getting the Cold Shoulder From Analysts
Uncover key insights on stocks with negative analyst sentiment, including major moves by Alphabet, Nike and ResMed. 
Via InvestorPlace
$1000 Invested In This Stock 15 Years Ago Would Be Worth $9,600 Today
Via Benzinga
Is NYSE:RMD a Good Fit for Dividend Investing?
Uncovering Dividend Opportunities with RESMED INC (NYSE:RMD). 
Via Chartmill
Beyond The Numbers: 6 Analysts Discuss ResMed Stock
Via Benzinga
ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
From ResMed Inc.
Via GlobeNewswire
How Great Is It to Have Customers That Absolutely Love You and Plan to Never Leave You?
We also talk about weight loss drugs and sleep apnea, and other stock market news. 
Via The Motley Fool
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. 
Via MarketBeat
Exposures Product Safety
(RMD) - Analyzing ResMed's Short Interest
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $11,000 Today
Via Benzinga
(RMD) - Analyzing ResMed's Short Interest
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
Via Benzinga
Sound Investments: 3 Stocks to Buy for a Good Night’s Rest
The safe stocks to buy for a good night’s rest aren’t the kind you’re thinking about. Nonetheless, they do make worthwhile investments. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why ResMed Shares Are Trading Lower Monday
ResMed stock is trading lower Monday after Eli Lilly and Company released data from a clinical trial in regards to the treatment of sleep apnea. 
Via Benzinga
ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday
Via Benzinga
Semiconductor, Nvidia Woes Deepen; Nasdaq 100 Slips, Dow Rallies; Bitcoin Sinks To $60,400: What's Driving Markets Monday?
Wall Street faces a continuation of last week’s trend during Monday’s morning trading, with semiconductor stocks selling off heavily and dragging down the tech sector, while the broader market remains... 
Via Benzinga
Topics Stocks
Exposures US Equities
Stocks Mixed As Investors Take Big Tech Profits
The major benchmarks are mixed today, as investors cycle out of the outperforming tech sector and buy into bank and energy stocks. 
Via Talk Markets
Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again
Eli Lilly tested its weight-loss drug in people with obesity suffering from sleep apnea events. 
Via Investor's Business Daily
Nasdaq Futures Slip As Nvidia Sell-Off Continues, S&P 500 Futures Hold Up: Analyst Says 'Valuations Will Go Parabolic And It Will Be A Perfect Time To Sell'
The U.S. 
Via Benzinga
Topics Stocks
Exposures US Equities
Elliott Wave Technical Forecast: Unlocking ASX Trading Success: ResMed Inc
The analysis aims to provide readers with insights into the current market trends and how to capitalize on them effectively. 
Via Talk Markets
PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
ResMed studies presented at SLEEP 2024 also revealed a 17% prevalence of insomnia among adults in North America, Latin America, and the Caribbean, and a higher rate of depression in women with OSA 
From ResMed Inc.
Via GlobeNewswire
Stryker Stock Sees RS Rating Treks Higher To 71
Stryker stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 63 to 71. 
Via Investor's Business Daily
$100 Invested In ResMed 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
From ResMed Inc.
Via GlobeNewswire
Betting on Nvidia: 3 ETFs to Own for Exposure to the AI Giant
Explore three ETFs with Nvidia exposure to capitalize on the future of AI without having to pick a single winner. 
Via InvestorPlace
Topics Artificial Intelligence ETFs
Exposures Artificial Intelligence
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
From ResMed Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.